Monday Morning’s Market Insights: Apple Inc. (AAPL), MannKind Corporation (MNKD), American Airlines Group Inc (AAL), Arrowhead Research Corp. (ARWR)
Apple Inc. (NASDAQ:AAPL) traded down 1.35% in pre-market trading this morning after analysts from Credit Suisse stated that Apple had decreased its component orders from suppliers by 10%. Some investors believe that this decrease signifies Apple’s weaker iPhone and iPad sales projections. However, these weak sales projections are for older models of the above. UBS analyst Steven Milunovich lowered his price target for Apple’s stock to $140 from $150, reiterating falling order concerns. Although he is not sure how falling orders will affect shipments, he states that “it is not encouraging” Similarly, one of Apple’s largest suppliers, Dialog Semiconductor, issued weak guidance for the quarter. Investors are concerned because this company generates 70% of its revenue from Apple, creating a link to the falling stock. According to TipRanks’ statistics, out of the 38 analysts who have rated Apple in the last 3 months, 29 gave a Buy rating while 9 remain on the sidelines. The average 12-month price target for Apple is $148.85, marking a 32.5% upside from where shares last closed.
MannKind Corporation (NASDAQ:MNKD) fell 3.69% in pre-market trading this morning following disappointing share sales to Israeli hedge funds. Last week, the company announced that it plans on selling 50 million shares on the Tel Aviv Stock Exchange. MannKind managed to only sell 13.8 million shares, generating only $36 million compared to its goal of between $115-$120 million. This move was intended to “provide MannKind with needed near term liquidity to support Afrezza operations and Technosphere developments.” According to TipRanks’ statistics, out of the 5 analysts who have rated MannKind in the last 3 months, 1 gave a Buy rating, 3 gave a Sell rating, and 1 remains on the sidelines. The average 12-month price target for MannKind is $1.50, marking a 38.52% downside from where shares last closed.
American Airlines Group Inc (NASDAQ:AAL) traded down close to 2% in pre-market trading this morning after Friday’s announcement of flight delays and cancellations to its US-Paris route due to the coordinated attacks. Passengers in France set to fly with American Airlines on Friday were reassigned to other airlines and did not have to pay a change fee. Some passengers cancelled their flights to Paris due to the security situation. The airline resumed its US-Paris route the following day. According to TipRanks’ statistics, out of the 5 analysts who have rated American Airlines in the past 3 months, 3 gave a Buy rating while 2 remain on the sidelines. The average 12-month price target for the stock is $53.40, marking a 23% upside from where shares last closed.
Arrowhead Research Corp. (NASDAQ:ARWR) rose 5% in pre-market trading today following the release of data regarding ARC-520, a drug which fights against chronic hepatitis B infection. The findings indicated that ARC-520 produced effective results in chimpanzees with chronic HBV. Similarly, the company reported that “HBV DNA integrated into the hosts genome” which produces HBV surface antigens in chimpanzees. The company also reported a difference in liver HBV DNA between HBeAG-negative chimps versus HBeAG-positive chimps. According to TipRanks’ statistics, only 1 analyst has rated ARWR in the last 3 months with a Buy rating. Their price target for the stock is $20.00, marking a 252% upside from where shares last closed.